How Engineered Antibodies Are Re-educating the Allergic Immune System

SCHLIEREN, Switzerland – November 03, 2026 — For decades, the global response to severe food and environmental allergies has been defined by a posture of defensive reactivity. Patients navigate the world armed with epinephrine auto-injectors, while the pharmaceutical industry has largely focused on managing the symptoms of accidental exposure or enduring the grueling, risk-laden process of oral immunotherapy. But a quiet revolution in biologic engineering is challenging this paradigm, suggesting that the human immune system can not only be shielded from allergens but actively re-educated to tolerate them.

Swiss biotechnology firm Mabylon AG has provided a compelling glimpse into this future. In a peer-reviewed study published today in Clinical & Experimental Allergy, the official journal of the British Society for Allergy & Clinical Immunology (BSACI), researchers demonstrated that Mabylon’s proprietary allergen-specific IgG4 antibodies do far more than simply intercept allergens. According to the data, these human-derived, half-life extended multi-specific antibodies actively redirect allergens toward tolerance-associated immune pathways, offering a tantalizing proof-of-concept for durable disease modification.

As global healthcare systems grapple with the rising economic and human costs of allergic diseases, this dual-action mechanism—providing immediate prophylactic protection while simultaneously rewiring the underlying immune response—could fundamentally alter the landscape of allergy therapeutics.

Beyond Symptom Suppression: The Mechanics of Immune Tolerance

To understand the significance of Mabylon’s findings, it is necessary to examine the traditional allergic cascade. In a peanut-allergic individual, exposure to specific peanut proteins triggers a rapid, aggressive response mediated by Immunoglobulin E (IgE) antibodies, leading to mast cell activation and the release of inflammatory mediators that cause anaphylaxis.

The new study, conducted in collaboration with Prof. Dr. R. J. Joost van Neerven of Wageningen University & Research, reveals a novel method of short-circuiting this process. In ex vivo experiments using cells from peanut-allergic patients, the introduction of allergen-specific IgG4 antibodies fundamentally altered the trajectory of the allergens. Instead of binding to B cells and triggering the inflammatory cascade, the allergens were redirected toward myeloid antigen-presenting cells.

This redirection is not merely a detour; it is a reprogramming event. The cellular shift was associated with a marked decrease in type 2 inflammatory cytokines—the primary drivers of allergic inflammation—and a corresponding increase in interleukin-10 (IL-10) and regulatory T-cell responses, which are the hallmarks of immune tolerance.

“Our antibodies are designed to neutralize allergens before they can trigger the allergic cascade. These new data show that they may also actively shape the immune response toward greater tolerance,” said Dr. Niccolò Pengo, Chief Scientific Officer of Mabylon AG. “This gives us a strong rationale to investigate both immediate protection and disease-modifying effects in our clinical programs.”

In a mouse model of peanut allergy, this mechanism translated into tangible physiological benefits. When combined with controlled allergen exposure, the IgG4 antibodies reduced mast-cell activation and halted the dangerous elevation of allergen-specific IgE that is typically observed during standard oral immunotherapy regimens.

Benchmarking Against the Biologics Landscape

The allergy treatment market is currently undergoing a biologic renaissance, but Mabylon’s approach represents a distinct strategic divergence from existing therapies.

Consider omalizumab, marketed as Xolair, which secured U.S. FDA approval in early 2024 for the prevention of allergic reactions to food allergens. Omalizumab is an anti-IgE antibody; it operates by mopping up free-floating IgE in the bloodstream, thereby reducing the ammunition available to mast cells. While effective at raising the threshold for allergic reactions, it requires injections every two to four weeks and does not fundamentally alter the patient's underlying sensitivity to the specific allergen.

Conversely, oral immunotherapy treatments like Palforzia attempt to build tolerance through daily, incremental exposure to peanut protein. However, this method requires strict adherence, carries a persistent risk of triggering the very anaphylaxis it seeks to prevent, and often fails to induce long-lasting tolerance once the daily dosing ceases.

Mabylon’s lead candidate, MY006, targets the allergens themselves—specifically the potent peanut proteins Ara h 2, Ara h 3, and Ara h 6—intercepting them before they can interact with the immune system. By combining this precise interception with the newly discovered tolerance-inducing redirection, Mabylon is attempting to merge the immediate safety profile of passive immunization with the holy grail of long-term disease modification.

The Clinical Frontier and Strategic Alliances

The translational leap from ex vivo human cells and murine models to human clinical efficacy is notoriously fraught with risk. However, Mabylon is already navigating this critical juncture.

MY006 is currently the subject of an ongoing Phase 1a/b clinical trial (NCT07287033). Following the successful dosing of healthy volunteers beginning in December 2025—which yielded a favorable safety profile—the trial has advanced to the patient portion, actively enrolling adolescents and adults with peanut allergies. Crucially, the trial is designed to evaluate not just safety and pharmacokinetics, but also pharmacodynamics and clinical activity, with Mabylon explicitly planning to monitor markers of disease modification.

Furthermore, the company is engineering these therapeutics for real-world practicality. By utilizing half-life extended antibodies, Mabylon aims to provide continuous protection with just two to four subcutaneous injections per year, a dramatic improvement in patient convenience compared to current biologic standards.

Behind the clinical science lies a formidable manufacturing and strategic architecture. Developing and manufacturing multi-specific, half-life extended antibodies is a complex, capital-intensive endeavor. To navigate this, Mabylon secured a pivotal collaboration in May 2024 through the Pfizer Ignite program. This alliance grants the Swiss biotech access to Pfizer’s vast research, development, and manufacturing services, effectively validating Mabylon's chemistry, manufacturing, and controls (CMC) processes while significantly de-risking the supply chain for its complex molecules.

Expanding the Platform: From Peanuts to Pollen

The strategic value of Mabylon’s platform extends far beyond the lucrative, albeit crowded, peanut allergy market. The Clinical & Experimental Allergy study confirmed that the same allergen-redirection mechanism observed with peanut proteins also occurred with birch-specific IgG4 antibodies targeting Bet v 1, the major birch pollen allergen.

This cross-class applicability is the foundation for Mabylon’s broader pipeline. The company's preclinical program, MY010, is a trispecific antibody designed to target birch, oak, and related tree-pollen allergens. Buoyed by the recent data and supported by its manufacturing alliances, MY010 has officially entered GMP (Good Manufacturing Practice) manufacturing, with clinical trials slated to begin in 2027.

“The significance of this work goes beyond a single allergy indication,” said Dr. Alcide Barberis, Chief Executive Officer of Mabylon AG. “It strengthens the biological rationale behind our allergen-neutralization platform and complements our antibody discovery and engineering capabilities. Our primary goal is to develop long-acting therapies that provide rapid protection. These findings suggest that this could potentially be complemented by modification of the underlying allergic immune response over time.”

As the biotechnology sector increasingly focuses on therapies that alter the root causes of chronic conditions, the data emerging from Schlieren suggests a profound shift. If the tolerance-associated immune effects observed in the laboratory translate into durable disease modification in human trials, the allergy therapeutics market will be forced to pivot. The era of merely managing the symptoms of allergic disease may soon give way to an era of active, engineered immune re-education, fundamentally redefining how modern medicine protects its most vulnerable patients.